Gavitt Woodard, MD

• Daniel Boffa
• Francesc Lopez-Giraldez
• Henry S. Park
• John Morton
• Roland Assi

Early Detection of Cancer

• Comparative genomics between matched solid and lepidic portions of semi-solid lung adenocarcinomasWoodard G, Ding V, Cho C, Brand N, Kratz J, Jones K, Jablons D. Comparative genomics between matched solid and lepidic portions of semi-solid lung adenocarcinomas. Lung Cancer 2023, 180: 107211. PMID: 37121213, PMCID: PMC10900430, DOI: 10.1016/j.lungcan.2023.107211.
• The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung CancerGrant M, Woodard G, Goldberg S. The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer. Hematology/Oncology Clinics Of North America 2023, 37: 513-531. PMID: 37024389, DOI: 10.1016/j.hoc.2023.02.003.
• 167 Comprehensive profiling of cancer-associated fibroblasts in CD8+T cell-exclusive non-small cell lung cancer tumor microenvironments using the Nanostring GeoMX® digital spatial profilerCho C, Woodard G, Lopez-Giraldez F, Badri T, Vesely M, Chen L. 167 Comprehensive profiling of cancer-associated fibroblasts in CD8+T cell-exclusive non-small cell lung cancer tumor microenvironments using the Nanostring GeoMX® digital spatial profiler. 2022, a179-a179. DOI: 10.1136/jitc-2022-sitc2022.0167.
• Thoracic CT follow-up after non-small-cell lung cancer resectionWoodard G, Boffa D, Blasberg J. Thoracic CT follow-up after non-small-cell lung cancer resection. The Lancet Oncology 2022, 23: e484. PMID: 36328013, DOI: 10.1016/s1470-2045(22)00618-0.
• Connection through cardiothoracic surgery subspecialty collaboration: Strategies for Early Faculty Peer Network DevelopmentLee M, Woodard G, Assi R. Connection through cardiothoracic surgery subspecialty collaboration: Strategies for Early Faculty Peer Network Development. JTCVS Open 2022, 12: 329-334. PMID: 36590730, PMCID: PMC9801233, DOI: 10.1016/j.xjon.2022.07.008.
• A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation— part 1: a guide to decision-makingDetterbeck FC, Blasberg JD, Woodard GA, Decker RH, Kumbasar U, Park HS, Mase VJ, Bade BC, Li AX, Brandt WS, Madoff DC. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation— part 1: a guide to decision-making. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813719, PMCID: PMC9264102, DOI: 10.21037/jtd-21-1823.
• A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 3: systematic review of evidence regarding surgery in compromised patients or specific tumorsBade BC, Blasberg JD, Mase VJ, Kumbasar U, Li AX, Park HS, Decker RH, Madoff DC, Brandt WS, Woodard GA, Detterbeck FC. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 3: systematic review of evidence regarding surgery in compromised patients or specific tumors. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813753, PMCID: PMC9264070, DOI: 10.21037/jtd-21-1825.
• A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 4: systematic review of evidence involving SBRT and ablationPark HS, Detterbeck FC, Madoff DC, Bade BC, Kumbasar U, Mase VJ, Li AX, Blasberg JD, Woodard GA, Brandt WS, Decker RH. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 4: systematic review of evidence involving SBRT and ablation. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813762, PMCID: PMC9264060, DOI: 10.21037/jtd-21-1826.
• A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 2: systematic review of evidence regarding resection extent in generally healthy patientsDetterbeck FC, Mase VJ, Li AX, Kumbasar U, Bade BC, Park HS, Decker RH, Madoff DC, Woodard GA, Brandt WS, Blasberg JD. A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 2: systematic review of evidence regarding resection extent in generally healthy patients. Journal Of Thoracic Disease 2022, 0: 0-0. PMID: 35813747, PMCID: PMC9264068, DOI: 10.21037/jtd-21-1824.
• Could Programmed Death-Ligand 1 Copy Number Alterations be a Predictive Biomarker for Immunotherapy Response?Woodard GA, Cho C, Chen L. Could Programmed Death-Ligand 1 Copy Number Alterations be a Predictive Biomarker for Immunotherapy Response? Journal Of Thoracic Oncology 2022, 17: 592-595. PMID: 35465963, DOI: 10.1016/j.jtho.2022.03.009.
• Discovering dominant tumor immune archetypes in a pan-cancer censusCombes A, Samad B, Tsui J, Chew N, Yan P, Reeder G, Kushnoor D, Shen A, Davidson B, Barczak A, Adkisson M, Edwards A, Naser M, Barry K, Courau T, Hammoudi T, Argüello R, Rao A, Olshen A, Consortium T, Spitzer M, Fong L, Nelson A, Kumar R, Lee J, Burra A, Hsu J, Hackett C, Tolentino K, Sjarif J, Johnson P, Shao E, Abrau D, Lupin L, Shaw C, Collins Z, Lea T, Corvera C, Nakakura E, Carnevale J, Alvarado M, Loo K, Chen L, Chow M, Grandis J, Ryan W, El-Sayed I, Jablons D, Woodard G, Meng M, Porten S, Okada H, Tempero M, Ko A, Kirkwood K, Vandenberg S, Guevarra D, Oropeza E, Cyr C, Glenn P, Bolen J, Morton A, Eckalbar W, Cai C, Zhan J, Davis K, Kelley R, Chapman J, Atreya C, Patel A, Daud A, Ha P, Diaz A, Kratz J, Collisson E, Fragiadakis G, Erle D, Boissonnas A, Asthana S, Chan V, Krummel M. Discovering dominant tumor immune archetypes in a pan-cancer census. Cell 2021, 185: 184-203.e19. PMID: 34963056, PMCID: PMC8862608, DOI: 10.1016/j.cell.2021.12.004.
• Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assayGupta AR, Woodard GA, Jablons DM, Mann MJ, Kratz JR. Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay. Future Oncology 2021, 17: 4785-4795. PMID: 34435876, PMCID: PMC9039775, DOI: 10.2217/fon-2021-0517.
• Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non–Squamous Non–Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant ChemotherapyWoodard GA, Kratz JR, Haro G, Gubens MA, Blakely CM, Jones KD, Mann MJ, Jablons DM. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non–Squamous Non–Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy. Clinical Lung Cancer 2021, 22: 587-595. PMID: 34544620, DOI: 10.1016/j.cllc.2021.08.008.
• Role of adjuvant therapy in T1-2N0 resected non–small cell lung cancerWoodard GA, Li A, Boffa DJ. Role of adjuvant therapy in T1-2N0 resected non–small cell lung cancer. Journal Of Thoracic And Cardiovascular Surgery 2021, 163: 1685-1692. PMID: 34334172, DOI: 10.1016/j.jtcvs.2021.05.053.
• Resectability, Recurrence, and Risk Stratification of Giant Solitary Fibrous Tumors in the Thoracic CavityWoodard GA, Fels Elliott DR, Yap A, Haro GJ, Kratz JR, Mann MJ, Jones KD, Jablons DM. Resectability, Recurrence, and Risk Stratification of Giant Solitary Fibrous Tumors in the Thoracic Cavity. Annals Of Surgical Oncology 2021, 28: 4953-4959. PMID: 33728541, DOI: 10.1245/s10434-021-09757-7.
• MO01.13 Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit from Adjuvant ChemotherapyWoodard G, Kratz J, Haro G, Gubens M, Blakely C, Jones K, Mann M, Jablons D. MO01.13 Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit from Adjuvant Chemotherapy. Journal Of Thoracic Oncology 2021, 16: s21. DOI: 10.1016/j.jtho.2020.10.061.
• Ponatinib is a potential therapeutic approach for malignant pleural mesotheliomaYang YW, Marrufo A, Chase J, Woodard GA, Jablons DM, Lemjabbar-Alaoui H. Ponatinib is a potential therapeutic approach for malignant pleural mesothelioma. Experimental Lung Research 2020, 47: 9-25. PMID: 33107354, DOI: 10.1080/01902148.2020.1836691.
• Everybody Must Get Scanned? Molecular Risk Stratification May Limit the Need for CT Surveillance Following Surgical Resection of Early-Stage Non-Squamous, Non-Small Cell Lung CancerHamilton B, Haro G, Woodard G, Sheu B, Kratz J, Mann M, Jablons D. Everybody Must Get Scanned? Molecular Risk Stratification May Limit the Need for CT Surveillance Following Surgical Resection of Early-Stage Non-Squamous, Non-Small Cell Lung Cancer. 2020, a7693-a7693. DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a7693.
• Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesotheliomaWoodard GA, Jablons DM. Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma. Translational Lung Cancer Research 2020, 9: s86-s91. PMID: 32206574, PMCID: PMC7082252, DOI: 10.21037/tlcr.2020.01.08.
• Comparison of Conventional TNM and Novel TNMB Staging Systems for Non–Small Cell Lung CancerHaro GJ, Sheu B, Cook NR, Woodard GA, Mann MJ, Kratz JR. Comparison of Conventional TNM and Novel TNMB Staging Systems for Non–Small Cell Lung Cancer. JAMA Network Open 2019, 2: e1917062. PMID: 31808928, PMCID: PMC6902768, DOI: 10.1001/jamanetworkopen.2019.17062.
• MA06.09 Timing of Driver Mutation Development and the Genetic Evolution of Semi-Solid Lung Nodules into Early NSCLCWoodard G, Ding V, Kim I, Jones K, Chavez G, Haro G, Kratz J, Mann M, Rotow J, Blakely C, Jablons D. MA06.09 Timing of Driver Mutation Development and the Genetic Evolution of Semi-Solid Lung Nodules into Early NSCLC. Journal Of Thoracic Oncology 2019, 14: s271-s272. DOI: 10.1016/j.jtho.2019.08.544.
• P2.06-09 Drop the Scalpel: Long-Term Survival in Mesothelioma Without Extrapleural Pneumonectomy or Pleurectomy DecorticationWoodard G, Crockard J, Anand A, Ding V, Jones K, Gubens M, Blakely C, Jahan T, Jablons D. P2.06-09 Drop the Scalpel: Long-Term Survival in Mesothelioma Without Extrapleural Pneumonectomy or Pleurectomy Decortication. Journal Of Thoracic Oncology 2019, 14: s758-s759. DOI: 10.1016/j.jtho.2019.08.1627.
• Case report: recurrent metastatic breast cancer in internal mammary dissection bed discovered at the time of coronary bypassWoodard GA, Lee H, Fels Elliott DR, Jones KD, Wong J, Jablons DM, Ihnken K. Case report: recurrent metastatic breast cancer in internal mammary dissection bed discovered at the time of coronary bypass. Journal Of Cardiothoracic Surgery 2019, 14: 158. PMID: 31488186, PMCID: PMC6728940, DOI: 10.1186/s13019-019-0980-1.
• Mesothelioma: Scientific clues for prevention, diagnosis, and therapyCarbone M, Adusumilli PS, Alexander HR, Baas P, Bardelli F, Bononi A, Bueno R, Felley‐Bosco E, Galateau‐Salle F, Jablons D, Mansfield AS, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang H, Zauderer MG, Pass HI. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA A Cancer Journal For Clinicians 2019, 69: 402-429. PMID: 31283845, PMCID: PMC8192079, DOI: 10.3322/caac.21572.
• Incorporation of a Molecular Prognostic Classifier Improves Conventional Non–Small Cell Lung Cancer StagingKratz JR, Haro GJ, Cook NR, He J, Van Den Eeden SK, Woodard GA, Gubens MA, Jahan TM, Jones KD, Kim IJ, He B, Jablons DM, Mann MJ. Incorporation of a Molecular Prognostic Classifier Improves Conventional Non–Small Cell Lung Cancer Staging. Journal Of Thoracic Oncology 2019, 14: 1223-1232. PMID: 30959120, DOI: 10.1016/j.jtho.2019.03.015.
• Cast of the Right Bronchial TreeWoodard GA, Wieselthaler GM. Cast of the Right Bronchial Tree. New England Journal Of Medicine 2018, 379: 2151-2151. PMID: 30485771, DOI: 10.1056/nejmicm1806493.
• Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping MutationRotow JK, Woodard GA, Urisman A, McCoach CE, Bivona TG, Elicker BM, Jablons DM, Blakely CM. Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation. Clinical Lung Cancer 2018, 20: e137-e141. PMID: 30553716, DOI: 10.1016/j.cllc.2018.11.003.
• MS31.03 Targeting the Hippo PathwayJablons D, Woodard G. MS31.03 Targeting the Hippo Pathway. Journal Of Thoracic Oncology 2018, 13: s306. DOI: 10.1016/j.jtho.2018.08.205.
• P3.03-24 Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer StagingHaro G, Kratz J, Cook N, He J, Van Den Eeden S, Woodard G, Gubens M, Jahan T, Jones K, Kim I, He B, Jablons D, Mann M. P3.03-24 Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging. Journal Of Thoracic Oncology 2018, 13: s919. DOI: 10.1016/j.jtho.2018.08.1701.
• P2.16-12 Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit from Adjuvant ChemotherapyWoodard G, Wang S, Kratz J, Haro G, Gubens M, Blakely C, Jahan T, Jones K, Mann M, Jablons D. P2.16-12 Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit from Adjuvant Chemotherapy. Journal Of Thoracic Oncology 2018, 13: s835. DOI: 10.1016/j.jtho.2018.08.1487.
• Scientific Advances and New Frontiers in Mesothelioma TherapeuticsMutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, Woodard GA, Jablons DM, Wiens J, Hirsch FR, Yang H, Carbone M, Thomas A, Hassan R. Scientific Advances and New Frontiers in Mesothelioma Therapeutics. Journal Of Thoracic Oncology 2018, 13: 1269-1283. PMID: 29966799, PMCID: PMC6643278, DOI: 10.1016/j.jtho.2018.06.011.
• 2460Wang S, Woodard G, Lucas C, Rogers S, Jablons D. 2460. Journal Of Clinical And Translational Science 2017, 1: 79-79. PMCID: PMC6799655, DOI: 10.1017/cts.2017.280.
• Drug development against the hippo pathway in mesotheliomaWoodard GA, Yang YL, You L, Jablons DM. Drug development against the hippo pathway in mesothelioma. Translational Lung Cancer Research 2017, 6: 335-342. PMID: 28713678, PMCID: PMC5504108, DOI: 10.21037/tlcr.2017.06.02.
• Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non–Small-Cell Lung CancerWoodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens MA, Jahan TM, Blakely CM, Jones KD, Mann MJ, Jablons DM. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2017, 19: 58-64. PMID: 28645632, DOI: 10.1016/j.cllc.2017.05.015.
• Melanotic SchwannomaWang S, Woodard G, Umetsu S, Tsai K, Daud A, Jones K, Jablons D. Melanotic Schwannoma. AJSP Review And Reports 2017, 22: 161-163. DOI: 10.1097/pcr.0000000000000200.
• Management of Lung Cancer Invading the Superior SulcusKratz JR, Woodard G, Jablons DM. Management of Lung Cancer Invading the Superior Sulcus. Thoracic Surgery Clinics 2017, 27: 149-157. PMID: 28363369, DOI: 10.1016/j.thorsurg.2017.01.008.
• P3.01-013 Case Report of Melanotic Schwannoma: A Challenging Diagnosis Made Clear through Genetic Testing Topic: MorphologyWang S, Woodard G, Rosenblum M, Zoon-Besselink C, Jones K, Jablons D. P3.01-013 Case Report of Melanotic Schwannoma: A Challenging Diagnosis Made Clear through Genetic Testing Topic: Morphology. Journal Of Thoracic Oncology 2017, 12: s1126. DOI: 10.1016/j.jtho.2016.11.1579.
• MA17.01 Microarray Identification of Genetic Drivers of Brain Metastasis in Lung AdenocarcinomaWoodard G, Ding V, Rosenblum M, Leguay F, Zoon-Besselink C, Jones K, Lea T, Mcdermott M, Kim I, Jablons D. MA17.01 Microarray Identification of Genetic Drivers of Brain Metastasis in Lung Adenocarcinoma. Journal Of Thoracic Oncology 2017, 12: s441-s442. DOI: 10.1016/j.jtho.2016.11.515.
• P1.03-066 Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer TNM Staging Topic: StagingKratz J, Cook N, Woodard G, Jones K, Gubens M, Jahan T, Kim I, He B, Jablons D, Mann M. P1.03-066 Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer TNM Staging Topic: Staging. Journal Of Thoracic Oncology 2017, 12: s584-s585. DOI: 10.1016/j.jtho.2016.11.738.
• OA19.06 Adjuvant Chemotherapy Decisions Based on Molecular Risk Status Improves Outcomes in Early Stage, Non-Small Cell Lung CancerWoodard G, Crockard J, Zoon-Besselink C, Kratz J, Gubens M, Jahan T, Blakely C, Jones K, Mann M, Jablons D. OA19.06 Adjuvant Chemotherapy Decisions Based on Molecular Risk Status Improves Outcomes in Early Stage, Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2017, 12: s320. DOI: 10.1016/j.jtho.2016.11.341.
• P2.04-039 Long-Term Risk of Recurrence in Benign Pleural Solitary Fibrous Tumors: A Single Institution Review Topic: Esophageal Cancer and Other MalignanciesWoodard G, Zoon-Besselink C, Wang S, Jones K, Jablons D. P2.04-039 Long-Term Risk of Recurrence in Benign Pleural Solitary Fibrous Tumors: A Single Institution Review Topic: Esophageal Cancer and Other Malignancies. Journal Of Thoracic Oncology 2017, 12: s1020-s1021. DOI: 10.1016/j.jtho.2016.11.1419.
• FAIM2, as a novel diagnostic maker and a potential therapeutic target for small-cell lung cancer and atypical carcinoidKang HC, Kim JI, Chang HK, Woodard G, Choi YS, Ku JL, Jablons DM, Kim IJ. FAIM2, as a novel diagnostic maker and a potential therapeutic target for small-cell lung cancer and atypical carcinoid. Scientific Reports 2016, 6: 34022. PMID: 27677402, PMCID: PMC5039724, DOI: 10.1038/srep34022.
• Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long‐term survival outcomes with minimal morbidityWoodard GA, Crockard JC, Clary‐Macy C, Zoon‐Besselink C, Jones K, Korn WM, Ko AH, Gottschalk AR, Rogers SJ, Jablons DM. Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long‐term survival outcomes with minimal morbidity. Journal Of Surgical Oncology 2016, 114: 838-847. PMID: 27569043, DOI: 10.1002/jso.24409.
• Lung Cancer Staging and PrognosisWoodard GA, Jones KD, Jablons DM. Lung Cancer Staging and Prognosis. 2016, 170: 47-75. PMID: 27535389, DOI: 10.1007/978-3-319-40389-2_3.
• Gli promotes epithelial-mesenchymal transition in human lung adenocarcinomasLi H, Yue D, Jin JQ, Woodard GA, Tolani B, Luh TM, Giroux-Leprieur E, Mo M, Chen Z, Che J, Zhang Z, Zhou Y, Wang L, Hao X, Jablons D, Wang C, He B. Gli promotes epithelial-mesenchymal transition in human lung adenocarcinomas. Oncotarget 2016, 5: 80415-80425. PMID: 27533453, PMCID: PMC5348330, DOI: 10.18632/oncotarget.11246.
• Consensus Report of the 2015 Weinman International Conference on MesotheliomaCarbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, Adjei A, Baumann F, Boffetta P, Buck B, de Perrot M, Dogan AU, Gavett S, Gualtieri A, Hassan R, Hesdorffer M, Hirsch FR, Larson D, Mao W, Masten S, Pass HI, Peto J, Pira E, Steele I, Tsao A, Woodard GA, Yang H, Malik S. Consensus Report of the 2015 Weinman International Conference on Mesothelioma. Journal Of Thoracic Oncology 2016, 11: 1246-1262. PMID: 27453164, PMCID: PMC5551435, DOI: 10.1016/j.jtho.2016.04.028.
• Abstract 108: Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomasKang H, Kim H, Lee S, Mendez P, Kim J, Woodard G, Jen K, Fang L, Jones K, Jablons D, Kim I. Abstract 108: Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. Cancer Research 2016, 76: 108-108. DOI: 10.1158/1538-7445.am2016-108.
• Significance of different response evaluation criteria in predicting progression‐free survival of lung cancer with certain imaging characteristicsYang D, Woodard G, Zhou C, Wang X, Liu Z, Ye Z, Li K. Significance of different response evaluation criteria in predicting progression‐free survival of lung cancer with certain imaging characteristics. Thoracic Cancer 2016, 7: 535-542. PMID: 27766777, PMCID: PMC5130210, DOI: 10.1111/1759-7714.12363.
• Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomasKang HC, Kim HK, Lee S, Mendez P, Kim JW, Woodard G, Yoon JH, Jen KY, Fang LT, Jones K, Jablons DM, Kim IJ. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. Oncotarget 2016, 7: 8321-8331. PMID: 26824986, PMCID: PMC4884995, DOI: 10.18632/oncotarget.7032.
• EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell CarcinomasYue D, Li H, Che J, Zhang Y, Tolani B, Mo M, Zhang H, Zheng Q, Yang Y, Cheng R, Jin JQ, Luh TW, Yang C, Tseng HH, Giroux-Leprieur E, Woodard GA, Hao X, Wang C, Jablons DM, He B. EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas. PLOS ONE 2015, 10: e0132134. PMID: 26132438, PMCID: PMC4488446, DOI: 10.1371/journal.pone.0132134.
• The Latest in Surgical Management of Stage IIIA Non-Small Cell Lung Cancer: Video-Assisted Thoracic Surgery and Tumor Molecular Profiling.Woodard GA, Jablons DM. The Latest in Surgical Management of Stage IIIA Non-Small Cell Lung Cancer: Video-Assisted Thoracic Surgery and Tumor Molecular Profiling. American Society Of Clinical Oncology Educational Book 2015, e435-41. PMID: 25993207, DOI: 10.14694/edbook_am.2015.35.e435.
• Prognostic Molecular Assay Might Improve Identification of Patients At Risk for Recurrence in Early-Stage Non–Small-Cell Lung CancerWoodard GA, Gubens MA, Jahan TM, Jones KD, Kukreja J, Theodore PR, Cardozo S, Jew G, Clary-Macy C, Jablons DM, Mann MJ. Prognostic Molecular Assay Might Improve Identification of Patients At Risk for Recurrence in Early-Stage Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2014, 15: 426-432. PMID: 25258195, DOI: 10.1016/j.cllc.2014.07.004.
• Normal Alcohol Metabolism after Gastric Banding and Sleeve Gastrectomy: A Case-Cross-Over TrialChangchien EM, Woodard GA, Hernandez-Boussard T, Morton JM. Normal Alcohol Metabolism after Gastric Banding and Sleeve Gastrectomy: A Case-Cross-Over Trial. Journal Of The American College Of Surgeons 2012, 215: 475-479. PMID: 22770864, DOI: 10.1016/j.jamcollsurg.2012.06.008.
• Laparoscopic vs Open Gastric Bypass Surgery: Differences in Patient Demographics, Safety, and OutcomesBanka G, Woodard G, Hernandez-Boussard T, Morton JM. Laparoscopic vs Open Gastric Bypass Surgery: Differences in Patient Demographics, Safety, and Outcomes. JAMA Surgery 2012, 147: 550-556. PMID: 22786543, DOI: 10.1001/archsurg.2012.195.
• Effect of Roux‐en‐Y gastric bypass on testosterone and prostate‐specific antigenWoodard G, Ahmed S, Podelski V, Hernandez‐Boussard T, Presti J, Morton J. Effect of Roux‐en‐Y gastric bypass on testosterone and prostate‐specific antigen. British Journal Of Surgery 2012, 99: 693-698. PMID: 22302466, DOI: 10.1002/bjs.8693.
• Halo Effect for Bariatric Surgery: Collateral Weight Loss in Patients' Family MembersWoodard GA, Encarnacion B, Peraza J, Hernandez-Boussard T, Morton J. Halo Effect for Bariatric Surgery: Collateral Weight Loss in Patients' Family Members. JAMA Surgery 2011, 146: 1185-1190. PMID: 22006878, DOI: 10.1001/archsurg.2011.244.
• Impaired Alcohol Metabolism after Gastric Bypass Surgery: A Case-Crossover TrialWoodard GA, Downey J, Hernandez-Boussard T, Morton JM. Impaired Alcohol Metabolism after Gastric Bypass Surgery: A Case-Crossover Trial. Journal Of The American College Of Surgeons 2010, 212: 209-214. PMID: 21183366, DOI: 10.1016/j.jamcollsurg.2010.09.020.
• Cardiac Arrest During Laparoscopic Roux-en-Y Gastric Bypass in a Bariatric Patient with Drug-Associated Long QT SyndromeWoodard G, Brodsky JB, Morton JM. Cardiac Arrest During Laparoscopic Roux-en-Y Gastric Bypass in a Bariatric Patient with Drug-Associated Long QT Syndrome. Obesity Surgery 2010, 21: 134-137. PMID: 20383601, DOI: 10.1007/s11695-010-0137-8.
• One Year Improvements in Cardiovascular Risk Factors: a Comparative Trial of Laparoscopic Roux-en-Y Gastric Bypass vs. Adjustable Gastric BandingWoodard GA, Peraza J, Bravo S, Toplosky L, Hernandez-Boussard T, Morton JM. One Year Improvements in Cardiovascular Risk Factors: a Comparative Trial of Laparoscopic Roux-en-Y Gastric Bypass vs. Adjustable Gastric Banding. Obesity Surgery 2010, 20: 578-582. PMID: 20186576, DOI: 10.1007/s11695-010-0088-0.
• Probiotics Improve Outcomes After Roux-en-Y Gastric Bypass Surgery: A Prospective Randomized TrialWoodard GA, Encarnacion B, Downey JR, Peraza J, Chong K, Hernandez-Boussard T, Morton JM. Probiotics Improve Outcomes After Roux-en-Y Gastric Bypass Surgery: A Prospective Randomized Trial. Journal Of Gastrointestinal Surgery 2009, 13: 1198-1204. PMID: 19381735, DOI: 10.1007/s11605-009-0891-x.
• Transglutaminase Induces Protofibril-like Amyloid β-Protein Assemblies That Are Protease-resistant and Inhibit Long-term Potentiation*Hartley DM, Zhao C, Speier AC, Woodard GA, Li S, Li Z, Walz T. Transglutaminase Induces Protofibril-like Amyloid β-Protein Assemblies That Are Protease-resistant and Inhibit Long-term Potentiation*. Journal Of Biological Chemistry 2008, 283: 16790-16800. PMID: 18397883, PMCID: PMC2423271, DOI: 10.1074/jbc.m802215200.